Comparison of the preparation of the radiopharmaceutical 68Ga-PSMA-11 at two Czech worksites

Česká verze

Authors: Michal Budinský; Vendula Janků
Published in the journal: Čes. slov. Farm., 2023; 72, 125-131
Category: Původní práce
doi: https://doi.org/10.5817/CSF2023-3-125

Summary

Radiopharmaceutical ⁶⁸Ga-PSMA-11 is one of the newest positron radiopharmaceuticals available for nuclear medicine departments in the Czech Republic. The radiopharmaceutical preparation can be carried out manually or instrumentally using modules for synthesis. Despite the greater technological difficulty of preparation, the success of synthesis of this radiopharmaceutical by both methods is very high, and the evaluated quality parameters of the radiopharmaceutical are comparable by both manual and instrumental preparation methods. Also, regarding professional exposure, the preparation of ⁶⁸Ga-PSMA-11 does not significantly affect the whole-body and finger dosimetry results.

Keywords:

Instrumentation – radiopharmacy – gallium-68 – 68Ga-PSMA-11

Zdroje

1. García Garzón J. R., de Arcocha Torres M., Delgado- Bolton R., Ceci F., Alvarez Ruiz S., Orcajo Rincón J., Caresia Aróztegui A. P., García Velloso M. J., García Vicente A. M. 68Ga-PSMA PET/CT in prostate cancer. Rev. Esp. Med. Nucl. Imagen Mol. (Engl. Ed.) 2018; 37(2), 130–138. doi: 10.1016/j.remn.2017.07.004

2. Erdoğan M., Özkan E. E., Öztürk S. A., Yıldız M., Şengül S. S. The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer. Mol. Imaging Radionucl. Ther. 2020; 29(3), 98–104. doi: 10.4274/mirt.galenos.2020.89421

3. Esen T., Kılıç M., Seymen H., Acar Ö., Demirkol M. O. Can Ga-68 PSMA PET/CT replace conventional imaging modalities for primary lymph node and bone staging of prostate cancer? Eur. Urol. Focus 2020; 6(2), 2018–2020. doi: 10.1016/j.euf.2019.05.005

4. Haberkorn U., Eder M., Kopka K., Babich J. W., Eisenhut M. New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. Clin. Cancer Res. 2016; 22(1), 9–15. doi: 10.1158/1078-0432.CCR-15-0820

5. Bertagna F., Albano D., Cerudelli E., Gazzilli M., Giubbini R., Treglia G. Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas. Current Radiopharmaceuticals 2020; 13, 94–98. doi: 10.2174/1874471012666191017093721

6. Kunikowska J., Cieślak B., Gierej B., Patkowski W., Kraj L., Kotulski M., Zieniewicz K., Królicki L. [68 Ga] Ga-Prostate-Specific Membrane Antigen PET/CT: a novel method for imaging patients with hepatocellular carcinoma. Eur. J. Nucl. Med. Mol. Imaging 2021; 48(3), 883–892. doi: 10.1007/s00259-020-05017-0.

7. Muzaffar S., Ahmed N., Rahman U., Al Kandari F., Usmani S. 68 Ga-Prostate-Specific Membrane Antigen Uptake as a Surrogate Biomarker of Neovascularity in Hepatocellular Carcinoma. Indian J. Nucl. Med. 2021; 36(1), 90–91. doi: 10.4103/ijnm.IJNM_38_20

8. Bertagna F., Albano D., Cerudelli E., Gazzilli M., Tomasini D., Bonu M., Giubbini R., Treglia G. Radiolabeled PSMA PET/CT in breast cancer. A systematic review. Nucl. Med. Rev. 2020; 23(1), 32–35. doi: 10.5603/NMR.2020.0004

9. Sathekge M., Modiselle M., Vorster M., Mokgoro N., Nyakale N., Mokaleng B., Ebenhan T. 68Ga-PSMA imaging of metastatic breast cancer. Eur. J. Nucl. Med. Mol. Imaging 2015; 42(9), 1482–1483. doi: 10.1007/s00259-015-3066-x

10. Kumar A., Ballal S.,Yadav M. P., ArunRaj S. T., Haresh K. P., Gupta S., Damle N. A., Garg A., Tripathi M., Bal Ch. 177Lu-/68Ga-PSMA Theranostics in Recurrent Glioblastoma Multiforme. Clin. Nucl. Med. 2020; 45(2), e512–e513. doi: 10.1097/RLU.0000000000003142

11. Kunikowska J., Charzyńska I., Kuliński R., Pawlak D., Maurin M., Królicki L. Tumor uptake in glioblastoma multiforme after IV injection of [177Lu] Lu-PSMA-617. Eur. J. Nucl. Med. Mol. Imaging 2020; 47(6), 1605–1606. doi: 10.1007/s00259-020-04715-z

12. Plichta K. A., Graves S. A., Buatti J. M. Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer. Int. J. Mol. Sci. 2021; 22(12095). doi: 10.3390/ijms222212095